ArticleTrials2021

Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.

Sonia Jaramillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.